- Home
- PLX vs HRTX Comparison
PLX vs HRTX Comparison
Compare PLX & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- HRTX
- Stock Information
- Founded
- PLX 1993
- HRTX 1983
- Country
- PLX United States
- HRTX United States
- Employees
- PLX N/A
- HRTX N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- HRTX Health Care
- Exchange
- PLX Nasdaq
- HRTX Nasdaq
- Market Cap
- PLX 204.9M
- HRTX 214.5M
- IPO Year
- PLX 1998
- HRTX 1987
- Fundamental
- Price
- PLX $2.19
- HRTX $1.10
- Analyst Decision
- PLX Strong Buy
- HRTX Strong Buy
- Analyst Count
- PLX 1
- HRTX 2
- Target Price
- PLX $15.00
- HRTX $4.50
- AVG Volume (30 Days)
- PLX 934.1K
- HRTX 1.9M
- Earning Date
- PLX 11-13-2025
- HRTX 11-04-2025
- Dividend Yield
- PLX N/A
- HRTX N/A
- EPS Growth
- PLX N/A
- HRTX N/A
- EPS
- PLX 0.08
- HRTX N/A
- Revenue
- PLX $61,948,000.00
- HRTX $155,097,000.00
- Revenue This Year
- PLX $14.53
- HRTX $10.62
- Revenue Next Year
- PLX $75.77
- HRTX $12.99
- P/E Ratio
- PLX $28.28
- HRTX N/A
- Revenue Growth
- PLX 62.79
- HRTX 12.60
- 52 Week Low
- PLX $1.16
- HRTX $1.04
- 52 Week High
- PLX $3.10
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- PLX 46.99
- HRTX 33.56
- Support Level
- PLX $2.25
- HRTX $1.06
- Resistance Level
- PLX $2.40
- HRTX $1.28
- Average True Range (ATR)
- PLX 0.14
- HRTX 0.08
- MACD
- PLX -0.02
- HRTX -0.01
- Stochastic Oscillator
- PLX 40.70
- HRTX 14.52
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.